ticker
stringlengths 2
5
| disease
stringlengths 3
196
| stage
stringclasses 15
values | date
stringlengths 19
19
| catalyst
stringlengths 18
760
| label
int64 -1
1
|
|---|---|---|---|---|---|
EIGR
|
Hutchinson-Gilford Progeria Syndrome (HGPS)
|
Approved
|
2020-11-20 00:00:00
|
FDA approval announced November 20, 2020.
| 1 |
GILD
|
Psoriatic arthritis
|
Phase 2
|
2018-05-30 00:00:00
|
Phase 2 data released May 30, 2018 - primary endpoint met.
| 0 |
AGEN
|
Solid cancers
|
Phase 1
|
2018-06-04 00:00:00
|
Phase 1 presentation at ASCO 2018. 31% ORR.
| 1 |
GSK
|
Anaemia in chronic kidney disease for patients on dialysis
|
Approved
|
2023-02-01 00:00:00
|
Approved February 1, 2023.
| 1 |
ITCI
|
Agitation in patients with dementia
|
Phase 2
|
2018-12-18 00:00:00
|
Phase 3 interim analysis December 18, 2018 noted trial to stop due to futility.
| -1 |
ABBV
|
Multiple myeloma
|
Phase 3
|
2021-12-13 00:00:00
|
Phase 3 overall survival results reported that there were 78 (40%) deaths in the treatment arm versus 36 (37%). Median OS was not reached in the treatment or placebo arm among all patients, noted December 13, 2021.
| 1 |
HGEN
|
Chronic myelomonocytic leukemia (CMML)
|
Phase 2
|
2023-04-14 00:00:00
|
Phase 2 preliminary study results reported that 6 subjects demonstrated clinical benefit, with ten grade 3/4 Serious Adverse Events, noted April 14, 2023.
| 1 |
SGEN
|
Frontline CD30-positive mature T-cell lymphomas - cancer
|
Approved
|
2018-11-16 00:00:00
|
FDA Approval announced November 16, 2018.
| 1 |
ASRT
|
Postherpetic neuralgia - shingles
|
Approved
|
2011-01-28 00:00:00
|
Approved January 28, 2011.
| 1 |
ITCI
|
Schizophrenia
|
Approved
|
2019-12-23 00:00:00
|
FDA Approval announced December 23, 2019.
| 1 |
RHHBY
|
Triple-negative breast cancer (TNBC)
|
Phase 3
|
2020-08-06 00:00:00
|
Phase 3 trial did not meet primary endpoint - October 6, 2020.
| 1 |
SQZ
|
Solid Tumors
|
Phase 1/2
|
2021-12-09 00:00:00
|
Phase 1/2 monotherapy data reported that of the five patients in this cohort, one patient showed a radiographic response and symptomatic improvement and reported a complete response, noted December 9, 2021.
| 1 |
AMGN
|
Rheumatoid Arthritis
|
Phase 2
|
2022-11-14 00:00:00
|
Phase 2 data reported that DAZ reduced DAS28-CRP and RF significantly vs. PBO at d113 in all dose regimens, noted November 14, 2022.
| 1 |
INTS
|
Solid tumors
|
Phase 1/2
|
2022-11-17 00:00:00
|
Phase 1/2 data reported at CTOS reported that patients who had 40% or more of their tumor burden treated with INT230-6, an exploratory analysis showed that overall survival was improved when compared to historical benchmarks, noted November 17, 2022.
| 1 |
MRK
|
Solid tumors
|
Phase 1/2
|
2023-08-09 00:00:00
|
Phase 1/2 sixth dose escalation cohort data and agent expansion data to showed durable anti-cancer activity observed during monotherapy dose escalation without dose-limiting toxicities. Late-stage pancreatic cancer patient achieved 80% tumor shrinkage with complete regression observed in two of three metastatic lesions in the liver in response to single-agent MDNA11, noted August 9, 2023.
| 1 |
SRPT
|
Duchenne muscular dystrophy
|
Approved
|
2021-02-25 00:00:00
|
FDA approval announced February 25, 2021.
| 1 |
MEIP
|
B-Cell Malignancies or Acute Myeloid Leukemia (AML)
|
Phase 1
|
2023-11-02 00:00:00
|
Phase 1 data from ASH abstract reported that at 200 mg, 5 of 10 AML pts (50%) had stable disease, noted November 2, 2023.
| 0 |
RHHBY
|
Neovascular Age-Related Macular Degeneration
|
Approved
|
2021-10-22 00:00:00
|
Approved October 22, 2021.
| 1 |
BLUE
|
β-Thalassemia
|
Approved
|
2022-08-17 00:00:00
|
Approved August 17, 2022.
| 1 |
MRK
|
Pneumococcal Vaccine in children
|
Approved
|
2022-06-22 00:00:00
|
Approved June 22, 2022.
| 1 |
INSM
|
Bronchiectasis
|
Phase 2
|
2020-02-03 00:00:00
|
Phase 2 trial met primary endpoint - February 3, 2020.
| 0 |
PFE
|
Diffuse Large B-cell Lymphoma (DLBCL), Cutaneous T-cell lymphoma (CTCL)
|
Phase 1
|
2017-12-11 00:00:00
|
Phase 1a/b updated data released at ASH 2017 - 5/18 objective response rate.
| 0 |
MRNS
|
Postpartum depression
|
Phase 2
|
2019-07-23 00:00:00
|
Phase 2 negative data released July 23, 2019.
| 0 |
ASMB
|
Hepatitis B virus (HBV)
|
Phase 2
|
2021-11-12 00:00:00
|
Phase 2 data reported that treatment led to a deeper level of viral suppression as measured by pgRNA and HBV DNA levels, noted November 12, 2021.
| 1 |
XERS
|
Endogenous Cushing’s syndrome
|
Approved
|
2021-12-30 00:00:00
|
Approved December 30, 2021.
| 1 |
MDWD
|
Basal Cell Carcinoma (BCC)
|
Phase 1/2
|
2023-07-10 00:00:00
|
Phase 1/2 data reported that treatment was safe and well-tolerated with eleven out of fifteen patients achieved complete clearance of their BCCs, noted July 10, 2023.
| 1 |
STTK
|
Solid Tumors or Lymphomas
|
Phase 1
|
2021-11-09 00:00:00
|
Phase 1 dose escalation data reported one confirmed partial response (PR), and a second unconfirmed PR, both in patients with PD-1/L1 inhibitor pretreated non-cutaneous melanoma, noted November 9, 2021.
| 1 |
TYRA
|
Achondroplasia
|
Phase 2
|
2023-08-01 00:00:00
|
FDA Orphan drug designation (ODD) granted on August 1, 2023.
| 0 |
RHHBY
|
Influenza
|
Approved
|
2018-10-24 00:00:00
|
FDA Approval announced October 24, 2018.
| 1 |
QNRX
|
Netherton Syndrome (NS)
|
Phase 1
|
2023-10-24 00:00:00
|
Phase 1 data from 6 subjects demonstrated well defined efficacy signals across a number of study endpoints, noted October 24, 2023.
| 1 |
PFE
|
Psoriatic arthritis
|
Approved
|
2017-12-14 00:00:00
|
Approval announced December 14, 2017.
| 1 |
ABBV
|
Non-radiographic axial spondyloarthritis
|
Approved
|
2022-10-21 00:00:00
|
FDA. Approved on October 21, 2022.
| 1 |
GSK
|
Mild to moderate COVID-19
|
Phase 3
|
2021-03-03 00:00:00
|
Independent Data and Safety Monitoring Board (DSMB) recommended that enrollment to be closed - raised concerns about the magnitude of potential benefit.
| 0 |
AMGN
|
Behçet’s Disease
|
Approved
|
2019-07-19 00:00:00
|
FDA Approval announced July 19, 2019.
| 1 |
RHHBY
|
Duchenne muscular dystrophy (DMD)
|
Phase 1b
|
2021-10-11 00:00:00
|
Phase 1b open label interim results from the first 11 participants in Cohort 1 (ambulatory boys aged 4-7 years) provided evidence of robust expression of micro-dystrophin and no new safety signals were identified, September 24, 2021. Functional results from study cohort 1 (n=11, ages 4-7) found participants improved 3.0 points on NSAA six months after treatment - noted October 11, 2021.
| 1 |
MRK
|
Pneumococcal conjugate vaccine
|
Phase 3
|
2023-07-27 00:00:00
|
Phase 3 trial met primary endpoint, noted July 27, 2023.
| 0 |
PFE
|
Ovarian cancer
|
Phase 3
|
2018-12-21 00:00:00
|
Phase 3 trial to be terminated due to lack of efficacy.
| -1 |
CANF
|
Psoriasis
|
Phase 3
|
2023-06-29 00:00:00
|
Phase 3 top-line data reported that trial met primary endpoint, noted June 29, 2022. Additionally in their Phase 3 the FDA encouraged the Company to enroll adolescent patients due to the strong safety profile of the drug demonstrated over the development history and prior clinical studies, noted June 29, 2023
| 1 |
CLNN
|
Multiple Sclerosis
|
Phase 2
|
2023-04-25 00:00:00
|
Phase 2 topline data presentated at AAN reported that the primary BC-LCLA outcome LS-mean difference was 3.13 and 2 of 3 key secondary outcomes were significant, noted April 25, 2023.
| 1 |
TEVA
|
Migraine
|
Approved
|
2018-09-14 00:00:00
|
FDA Approval announced September 14, 2018.
| 1 |
MEIP
|
Acute Myeloid Leukemia
|
Phase 3
|
2020-07-02 00:00:00
|
Phase 3 trial discontinued due to lack of efficacy - July 2, 2020.
| -1 |
PFE
|
HIV
|
Approved
|
2022-02-01 00:00:00
|
Approved February 1, 2022.
| 1 |
VALN
|
Chikungunya Virus Infection
|
Phase 3
|
2021-08-05 00:00:00
|
Phase 3 trial met primary endpoint - August 5, 2021.
| 0 |
AMGN
|
Osteoporosis
|
Approved
|
2019-04-09 00:00:00
|
FDA Approval announced April 9, 2019.
| 1 |
ETON
|
Allergic conjunctivitis
|
Approved
|
2020-09-25 00:00:00
|
FDA approval announced September 25, 2020.
| 1 |
IMMX
|
Solid tumors
|
Phase 1/2
|
2023-07-17 00:00:00
|
Phase 1b/2a additional data noted that tumor shrinkage was observed in 3 out of 4 (75%) patients; 1 out of 4 (25%) experienced tumor control as of the July 7, 2023 clinical data cutoff date. All patients had stage IV relapsed/refractory metastatic colorectal cancer and received 8 median lines of therapy prior to IMX-110 + tislelizumab, noted July 17, 2023.
| 1 |
JSPR
|
Fanconi Anemia (FA)
|
Phase 1b
|
2023-09-21 00:00:00
|
Phase 1b updated results showed that all three patients treated achieved full donor engraftment and full blood count recovery. Briquilimab was well tolerated without any complications, noted September 21, 2023.
| 1 |
MRK
|
First-line ovarian cancer following platinum-based chemotherapy
|
Approved
|
2018-12-19 00:00:00
|
FDA Approval announced December 19, 2018.
| 1 |
CORT
|
Antipsychotic-induced weight gain (APIWG)
|
Phase 2
|
2022-12-08 00:00:00
|
Phase 2 data reported that AIWG did not reverse, noted December 8, 2022.
| 0 |
HALO
|
Chronic inflammatory demyelinating polyneuropathy (CIDP)
|
Phase 2
|
2023-07-17 00:00:00
|
Phase 2 trial met primary endpoints, noted July 17, 2023.
| 0 |
RHHBY
|
Spinal Muscular Atrophy (SMA) Type 1
|
Approved
|
2020-08-07 00:00:00
|
FDA Approval announced August 7, 2020.
| 1 |
TAK
|
Dravet Syndrome / Lennox-Gastaut Syndrome
|
Phase 3
|
2023-04-27 00:00:00
|
Phase 3 data reported that 78% of patients tolerated the highest dose level well with sustained reduction in frequency of drop seizures, noted April 27, 2023.
| 1 |
MRUS
|
Solid tumors
|
Phase 1
|
2021-12-06 00:00:00
|
Phase 1 data demonstrated preliminary evidence of antitumor activity has been observed at doses ≥25 mg biweekly, median duration was approximately 6 (1–74) weeks. TEAEs occurred in 33 patients (97.1%); treatment-related TEAEs occurred in 23 patients (67.6%), most commonly fatigue and decreased neutrophil count, noted December 6, 2021.
| 1 |
XENE
|
Postherpetic neuralgia
|
Phase 2b
|
2017-06-27 00:00:00
|
Phase 2b data released June 27, 2017. Endpoints not met.
| 0 |
RDHL
|
COVID-19
|
Phase 2/3
|
2022-02-07 00:00:00
|
Phase 2/3 data reported significantly reduced mortality when given to patients who received standard-of-care (SoC), as well as a significant benefit in time to recovery, noted February 7, 2022.
| 1 |
PFE
|
Squamous cell carcinoma of the head and neck (SCCHN)
|
Phase 2
|
2023-04-17 00:00:00
|
Phase 2 interim results presented at AACR reported a confirmed ORR of 40%, with one complete response and 5 partial responses, noted April 17, 2023.
| 1 |
XENT
|
Recurrent sinus obstruction
|
Approved
|
2017-12-11 00:00:00
|
Approval announced December 11, 2017.
| 1 |
CMPX
|
Biliary Tract Cancer (cholangiocarcinoma)
|
Phase 2
|
2023-01-19 00:00:00
|
Phase 2 data presented at ASCO GI reported a 37.5% overall response rate (ORR) in 24 patients, and an ORR of 63.6% in a sub-group analysis, noted January 19, 2023.
| 1 |
AMGN
|
Plaque psoriasis
|
Approved
|
2021-12-20 00:00:00
|
Approved December 20, 2021.
| 1 |
BMY
|
AML Maintenance
|
Approved
|
2020-09-01 00:00:00
|
FDA approval announced September 1, 2020.
| 1 |
AZN
|
Metastatic Breast Cancer
|
Phase 1/2
|
2022-12-09 00:00:00
|
Phase 1/2 presentation reported that treatment significantly reduced risk of death by 36%, noted December 9, 2022.
| 1 |
RGEN
|
Detection of pancreatic duct abnormalities
|
CRL
|
2012-06-22 00:00:00
|
CRL received June 22, 2012.
| 0 |
OTLK
|
Wet age-related macular degeneration (wet AMD)
|
Phase 3
|
2021-10-12 00:00:00
|
Phase 3 safety data showed no intraocular inflammation or vasculitis, and the frequency and incidence of adverse events and ocular adverse events were low. The most common adverse event in the study eye conjunctival hemorrhage related to injection procedure, not to ONS-5010, and there were no additional serious adverse events associated with these injections, noted October 12, 2021.
| 1 |
ARWR
|
Cardiovascular disease / Elevated Lipoprotein
|
Phase 2
|
2023-08-28 00:00:00
|
Phase 2 data reported at ESC noted that results from the off-treatment extension period show that patients previously dosed with ≥75 mg of olpasiran sustained a ~40-50% placebo-adjusted percent reduction in Lp(a) nearly a year after the last dose, noted August 28, 2023.
| 1 |
RHHBY
|
Non-small cell lung cancer (NSCLC)
|
Phase 3
|
2022-08-01 00:00:00
|
Phase 3 trial met co-primary endpoints, noted August 2, 2022. Regulatory filing planned.
| 0 |
PFE
|
Pneumococcal conjugate vaccine (18 yrs +)
|
Approved
|
2021-06-08 00:00:00
|
https://www.businesswire.com/news/home/20210608006149/en/
| 0 |
REGN
|
Non-Hodgkin Lymphoma (NHL)
|
Phase 2
|
2022-12-12 00:00:00
|
Phase 2 data presented at ASH showed a 49% ORR in heavily pre-treated patients who were naïve to prior CAR-T, with 31% achieving a complete response (CR), noted December 12, 2022.
| 1 |
ATNM
|
Acute myeloid leukemia (AML)
|
Phase 3
|
2023-06-12 00:00:00
|
Additional Phase 3 data at EHA presented results demonstrate unprecedented bone marrow transplant access and outcomes with Iomab-B on June 12, 2023
| 1 |
EXEL
|
Thyroid Carcinoma
|
Phase 3
|
2021-09-20 00:00:00
|
Phase 3 data showed a median progression-free survival was 11.0 months for CABOMETYX compared with 1.9 months for placebo. Objective response rate (ORR) favored CABOMETYX at 11%, including one complete response, versus 0% for placebo. Median overall survival was 19.4 months, September 20, 2021.
| 1 |
IGXT
|
Migraine
|
CRL
|
2020-03-27 00:00:00
|
CRL announced March 27, 2020.
| 0 |
RGLS
|
Alport Syndrome
|
Phase 2
|
2022-07-15 00:00:00
|
Phase 2 trial terminated after failing to meet pre-defined futility criteria, noted July 15, 2022.
| 1 |
EXEL
|
Advanced Neuroendocrine Tumors
|
Phase 3
|
2023-10-23 00:00:00
|
Phase 3 data from ESMO 23 reported that the trial met the primary objective for each cohort, demonstrating that cabozantinib provided dramatic improvements in median progression-free survival (PFS) for the patients in the pNET and epNET cohorts, noted October 23, 2023.
| 1 |
AVRO
|
Cystinosis
|
Phase 1/2
|
2023-05-18 00:00:00
|
Phase 1/2 data presented at ASGCT reported sustained engraftment and durable reduction in leukocyte cystine levels across all patients, noted May 18, 2023.
| 1 |
NGM
|
NASH cirrhosis
|
Phase 2b
|
2023-05-08 00:00:00
|
Phase 2b top-line data demonstrated statistically significant reductions in serum 7αC4 (a marker of bile acid synthesis) and fecal bile acids versus placebo in patients with idiopathic BAM with IBS-D, noted May 8, 2023.
| 1 |
MRK
|
Untreated locally advanced or metastatic urothelial cancer (la/mUC)
|
Phase 3
|
2023-10-23 00:00:00
|
Phase 3 data presented at ESMO reported a median OS of 31.5 months (95% CI: 25.4-NR) compared to 16.1 months in the chemotherapy arm, significantly prolonged OS, reducing the risk of death by 53% compared to treatment with chemotherapy, noted October 23, 2023.
| 1 |
NOVN
|
Acne vulgaris
|
Phase 3
|
2017-01-27 00:00:00
|
Phase 3 top-line data released January 27, 2017. Met one of three co-primary endpoints in NI-AC301 trial. Met all endpoints in NI-AC302 trial.
| 0 |
BMRN
|
Duchenne Muscular Dystrophy (DMD)
|
CRL
|
2016-01-14 00:00:00
|
CRL issued January 14 2016.
| 0 |
ENLV
|
COVID-19
|
Phase 2
|
2021-02-03 00:00:00
|
Phase 2 data released February 3, 2021. 14/16 (87.5%) patients recovered and were discharged from the hospital by day-28.
| 0 |
IMVIQ
|
Platinum Resistant Ovarian Cancer
|
Phase 2
|
2021-12-09 00:00:00
|
Phase 2 data reported increases in both T and B cell immune infiltration, and more prominent antigen-specific humoral responses, noted December 9, 2021.
| 0 |
SMMT
|
Non-small cell lung cancer (NSCLC)
|
Phase 2
|
2023-06-05 00:00:00
|
Phase 2 data reported a median progression-free survival (PFS) of 11.0 months and an overall response rate (ORR) of 67%, noted June 5, 2023.
| 0 |
BHC
|
Psoriasis
|
Approved
|
2017-02-15 00:00:00
|
Approved February 15, 2017.
| 1 |
LGND
|
Chronic obstructive pulmonary disease (COPD)
|
Phase 2
|
2021-10-13 00:00:00
|
Phase 2 part B data noted when administered by hand-held pMDI over one week treatment provided clinically meaningful, statistically significant and dose-dependent bronchodilation, noted October 13, 2021.
| 1 |
JNJ
|
Crohn's disease
|
Phase 3
|
2023-10-16 00:00:00
|
Phase 3 data reported that in the combination 54% of patients reached a clinical remission, noted October 16, 2023.
| 1 |
GMAB
|
Follicular lymphoma (FL)
|
Phase 1/2
|
2023-06-28 00:00:00
|
Phase 1/2 FL cohort data reported an overall response rate (ORR) of 82% and that the median duration of response (DOR) was not reached, noted June 28, 2023.
| 1 |
PFE
|
BRAFV600E-mutant metastatic non-small cell lung cancer (NSCLC)
|
Approved
|
2023-10-12 00:00:00
|
Approved October 12, 2023.
| 1 |
ATHE
|
Multiple System Atrophy (MSA)
|
Phase 2
|
2023-07-26 00:00:00
|
Phase 2 trial recommended by DMC on July 26, 2023.
| 0 |
EIGR
|
Post-Bariatric Hypoglycemia (PBH)
|
Phase 2
|
2018-10-16 00:00:00
|
Phase 2 data released October 16, 2018 - endpoints met.
| 0 |
NVO
|
Hemophilia A and B
|
CRL
|
2023-05-04 00:00:00
|
CRL received noted May 4, 2023.
| 0 |
UNCY
|
Hyperphosphatemia
|
Phase 1
|
2022-12-28 00:00:00
|
Trial met primary endpoint, noted December 28, 2022
| 0 |
INMB
|
Neuroinflammation caused by Alzheimer’s disease
|
Phase 2
|
2023-10-24 00:00:00
|
Phase 2 presentation at CTAD reported that XPro was associated with dose-dependent improvement in neurology-related proteins, noted October 24, 2023.
| 1 |
XERS
|
Severe hypoglycemia
|
Approved
|
2019-09-10 00:00:00
|
FDA Approval issued September 10, 2019.
| 1 |
CRBU
|
B-Cell Non-Hodgkin Lymphoma
|
Phase 1
|
2023-07-13 00:00:00
|
Phase 1 update reported a 94% overall response rate (ORR), 69% complete response (CR) rate, and 44% CR rate at ≥6 months following a single dose of CB-010, with 24 months as the longer CR maintained to date, noted July 13, 2023.
| 0 |
CYTK
|
Heart failure with reduced ejection fraction (HFrEF)
|
CRL
|
2023-02-28 00:00:00
|
CRL issued February 28, 2023.
| 0 |
AGIO
|
IDH1m Relapsed/Refractory AML - cancer
|
Approved
|
2018-07-20 00:00:00
|
FDA Approval announced July 20, 2018.
| 1 |
SAGE
|
Essential tremor
|
Phase 2
|
2021-04-12 00:00:00
|
Phase 2 trial met primary endpoint (P=0.049) - April 12, 2021. 62% of patients were down-titrated to from 60mg to 45 mg or 30 mg with the high dose not well tolerated.
| 1 |
AMGN
|
Thyroid Eye Disease (TED)
|
Approved
|
2020-01-21 00:00:00
|
FDA Approval announced January 21, 2020.
| 1 |
ELOX
|
Cystic fibrosis
|
Phase 2
|
2023-06-14 00:00:00
|
Phase 2 data demonstrated clinically relevant improvement in percent predicted forced expiratory volume (ppFEV1) based on final data assessment, noted June 14, 2023.
| 1 |
PFE
|
COVID-19 vaccine
|
Approved
|
2022-06-17 00:00:00
|
EUA approval for children 4 years - 6 months, noted June 17, 2022.
| 1 |
CYCN
|
Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like Episodes (MELAS)
|
Phase 2
|
2022-06-28 00:00:00
|
Phase 2 data reported that treatment was well tolerated, with no reports of serious adverse events (SAEs) or treatment discontinuation due to adverse events (AEs), and showed improvements across multiple mitochondrial disease-associated biomarkers, inflammatory biomarkers, cerebral blood flow, and functional connectivity between neural networks, noted June 28, 2022.
| 1 |
PGEN
|
Myelodysplastic Syndromes, Acute Myeloid Leukemia
|
Phase 1b
|
2022-12-13 00:00:00
|
Phase 1/1b data reported a 27% objective response rate (ORR) in heavily pre-treated r/r AML patients, noted December 13, 2022.
| 1 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.